Eli Lilly: Retatrutide sets new clinical benchmarks and boosts revenue and profit!

The US pharmaceutical company Eli Lilly intensifies competition in the market for obesity and metabolic therapies. New study data on the experimental drug Retatrutide shows significant medical relevance. With this, Eli Lilly is fundamentally shifting the accents in a competitive environment where effective weight reduction is one of the most important growth drivers of the global pharmaceutical industry. Retatrutide leads to weight reduction in nearly 30% of cases In a pivotal phase-3 study, Retatrutide achieved extraordinary results in overweight...